Literature DB >> 10735511

Activated mesothelial cells produce heparin-binding growth factors: implications for tumour metastases.

D G Jayne1, S L Perry, E Morrison, S M Farmery, P J Guillou.   

Abstract

Curative surgery for gastrointestinal malignancy is commonly thwarted by local tumour recurrence. The heparin-binding growth factors, basic fibroblast growth factor (bFGF), heparin-binding epidermal growth factor-like growth factor (HB-EGF) and vascular epidermal growth factor (VEGF) are all implicated in the metastatic process, but whether or not these essential growth factors are produced by the activated peritoneum is unknown. This study reveals that peritoneal mesothelial cells constitutively express mRNA for bFGF, HB-EGF and two VEGF spliced variants, VEGF121 and VEGF165. Mesothelial activation with interleukin (IL)-1b or tumour necrosis factor (TNF)-a produced an up-regulation of mRNA for HB-EGF and VEGF, but not bFGF expression. IL-6 failed to stimulate growth factor expression, whereas IL-2 produced a marked suppression in HB-EGF and bFGF, but not VEGF expression. Mesothelial cells were shown to predominantly express mRNA for the intermediate affinity (bg(c)) IL-2 receptor. Cytokine-induced growth factor up-regulation was confirmed at the protein level using Western blotting of mesothelial cell lysates for HB-EGF and culture supernatant enzyme-linked immunosorbent assay for VEGF. The production of these growth factors by human mesothelial cells may play a significant role in post-operative peritoneal tumour recurrence. Their common heparin-binding property offers a potential therapeutic target for manipulating the growth factor environment of the human peritoneum.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10735511      PMCID: PMC2363354          DOI: 10.1054/bjoc.1999.1068

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

1.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation.

Authors:  A C Rapraeger; A Krufka; B B Olwin
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

2.  Transforming growth factor alpha is trophic to pancreatic cancer in vivo.

Authors:  N Davies; P Kapur; J Gillespie; P J Guillou; G J Poston
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

3.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

Authors:  K A Houck; N Ferrara; J Winer; G Cachianes; B Li; D W Leung
Journal:  Mol Endocrinol       Date:  1991-12

4.  Inhibition of peritoneal tumor-cell implantation: model for laparoscopic cancer surgery.

Authors:  D S Goldstein; M L Lu; T Hattori; T L Ratliff; K R Loughlin; L R Kavoussi
Journal:  J Endourol       Date:  1993-06       Impact factor: 2.942

5.  Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro.

Authors:  M S Pepper; N Ferrara; L Orci; R Montesano
Journal:  Biochem Biophys Res Commun       Date:  1992-12-15       Impact factor: 3.575

6.  Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1.

Authors:  L Lanfrancone; D Boraschi; P Ghiara; B Falini; F Grignani; G Peri; A Mantovani; P G Pelicci
Journal:  Blood       Date:  1992-12-01       Impact factor: 22.113

Review 7.  Paracrine growth regulation of human colon carcinoma organ-specific metastasis.

Authors:  R Radinsky
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

8.  Expression of fibroblast growth factor gene family and its receptor gene family in the human upper gastrointestinal tract.

Authors:  S Iida; O Katoh; A Tokunaga; M Terada
Journal:  Biochem Biophys Res Commun       Date:  1994-03-30       Impact factor: 3.575

9.  Fibroblast growth factors modulate intestinal epithelial cell growth and migration.

Authors:  A U Dignass; S Tsunekawa; D K Podolsky
Journal:  Gastroenterology       Date:  1994-05       Impact factor: 22.682

10.  Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors.

Authors:  J Gillespie; J F Dye; M Schachter; P J Guillou
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

View more
  8 in total

1.  Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.

Authors:  Suguru Dateoka; Yuichi Ohnishi; Kenji Kakudo
Journal:  Med Mol Morphol       Date:  2012-06-21       Impact factor: 2.309

2.  Tks5 activation in mesothelial cells creates invasion front of peritoneal carcinomatosis.

Authors:  R Satoyoshi; N Aiba; K Yanagihara; M Yashiro; M Tanaka
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

3.  Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression.

Authors:  Hui-Wen Lo; Sheng-Chieh Hsu; Weiya Xia; Xinyu Cao; Jin-Yuan Shih; Yongkun Wei; James L Abbruzzese; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

4.  The role of human peritoneal mesothelial cells in the fibrosis and progression of gastric cancer.

Authors:  Tomoya Tsukada; Sachio Fushida; Shinichi Harada; Yasumichi Yagi; Jun Kinoshita; Katsunobu Oyama; Hidehiro Tajima; Hideto Fujita; Itasu Ninomiya; Takashi Fujimura; Tetsuo Ohta
Journal:  Int J Oncol       Date:  2012-05-18       Impact factor: 5.650

5.  Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer.

Authors:  H Yagi; S Miyamoto; Y Tanaka; K Sonoda; H Kobayashi; T Kishikawa; R Iwamoto; E Mekada; H Nakano
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

Review 6.  Angiogenesis-related pathways in the pathogenesis of ovarian cancer.

Authors:  Nikos G Gavalas; Michalis Liontos; Sofia-Paraskevi Trachana; Tina Bagratuni; Calliope Arapinis; Christine Liacos; Meletios A Dimopoulos; Aristotle Bamias
Journal:  Int J Mol Sci       Date:  2013-07-30       Impact factor: 5.923

7.  Exosomal miR-21-5p derived from gastric cancer promotes peritoneal metastasis via mesothelial-to-mesenchymal transition.

Authors:  Qiang Li; Bowen Li; Qing Li; Song Wei; Zhongyuan He; Xiaoxu Huang; Lu Wang; Yiwen Xia; Zhipeng Xu; Zheng Li; Weizhi Wang; Li Yang; Diancai Zhang; Zekuan Xu
Journal:  Cell Death Dis       Date:  2018-08-28       Impact factor: 8.469

8.  Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours.

Authors:  Arash Rafii; Pejman Mirshahi; Mary Poupot; Anne-Marie Faussat; Anne Simon; Elodie Ducros; Eliane Mery; Bettina Couderc; Raphael Lis; Jerome Capdet; Julie Bergalet; Denis Querleu; Francoise Dagonnet; Jean-Jacques Fournié; Jean-Pierre Marie; Eric Pujade-Lauraine; Gilles Favre; Jeanine Soria; Massoud Mirshahi
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.